Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
Ann Intensive Care
.
2023 Sep 29;13(1):95.
doi: 10.1186/s13613-023-01194-x.
Authors
Sylvie Chevret
1
,
Lila Bouadma
2
3
,
Claire Dupuis
3
4
,
Charles Burdet
3
5
,
Jean-Francois Timsit
6
7
;
COVIDICUS RCT group
Affiliations
1
ECSTRRA, UMR 1153, Saint Louis Hospital, University Paris Cité, Paris, France.
2
Medical and Infectious Diseases ICU, APHP Bichat Hospital, 75018, Paris, France.
3
Université Paris Cité, IAME, INSERM, UMR 1137, 75018, Paris, France.
4
Intensive Care Unit, Gabriel Montpied Hospital, CHU de Clermont-Ferrand, 63000, Clermont-Ferrand, France.
5
Epidemiology, Biostatistics and Clinical Research Department, AP-HP, Bichat Hospital, 75018, Paris, France.
6
Medical and Infectious Diseases ICU, APHP Bichat Hospital, 75018, Paris, France. Jean-francois.timsit@bch.aphp.fr.
7
Université Paris Cité, IAME, INSERM, UMR 1137, 75018, Paris, France. Jean-francois.timsit@bch.aphp.fr.
PMID:
37773550
PMCID:
PMC10541350
DOI:
10.1186/s13613-023-01194-x
No abstract available
Publication types
Published Erratum